A leading biotechnology company with a focus on development and commercialization of gene therapies for bleeding and other debilitating disorders had developed a next-generation AAV gene therapy platform. The company wanted to build its pipeline with other drugs against autoimmune and complement-mediated diseases. Along with support from investors, they were in the process of evaluating a long list of potential indications in terms of technical feasibility with their platform technology, and approached Alacrita to support additional appraisal of short-listed indications for prioritization.
Alacrita supported the client by engaging an experienced consultant with a background in building and delivering innovative therapeutic portfolios within the immunology/inflammatory disease field through both internal and in-licensed projects. Based on his expert knowledge around the scientific, clinical and commercial landscape in immunology/inflammation and respiratory diseases, we conducted an appraisal of the preclinical and early clinical path in 14 different target indications against the technical capabilities of the company's gene technology. A report was developed in PowerPoint format and presented to the board of the company.
Gene Therapy Consulting
Alacrita frequently supports client programs in the gene therapy space, with our expertise spanning a range of therapeutic areas and functional disciplines.Back